ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference

LYON, France–(BUSINESS WIRE)–Regulatory News:

ERYTECH Pharma (Nasdaq and Euronext: ERYP), a clinical-stage
biopharmaceutical company developing innovative therapies by
encapsulating therapeutic drug substances inside red blood cells, today
announced that Gil Beyen, Chairman and Chief Executive Officer, will
present at the Jefferies Global Healthcare on November 15
th,
2017 at the Waldorf Hilton Hotel (Aldwych) in London, UK.

Conference Details:

  • Conference: Jefferies Global Healthcare Conference
  • Date: November 15, 2017
  • Presentation Time: 2:00 PM GMT/ 9:00 AM ET

A live webcast of the Jefferies Global Healthcare presentation will be
available online from the investor relations page of the company’s
corporate website at www.erytech.com/webcast.com.
After the live webcast, an archive of the presentation will be available
on the company website for 30 days.

About ERYTECH and eryaspase (GRASPA®): www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage
biopharmaceutical company developing innovative therapies for rare forms
of cancer and orphan diseases. Leveraging its proprietary ERYCAPS
platform, which uses a novel technology to encapsulate therapeutic drug
substances inside red blood cells, ERYTECH has developed a pipeline of
product candidates targeting markets with high unmet medical needs.
ERYTECH’s initial focus is on the development of products that target
the amino acid metabolism of cancer, depriving them of nutrients
necessary for their survival.

The company’s lead product, eryaspase, also known under the trade name
GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside
donor-derived red blood cells. L-asparaginase depletes asparagine, a
naturally occurring amino acid essential for the survival and
proliferation of cancer cells. L-asparaginase has been a standard
component of multi-agent chemotherapy for the treatment of acute
lymphoblastic leukemia (ALL), but side effects limit treatment
compliance, especially in adults and patients with weak performance
status. With its improved safety profile, eryaspase aims to provide
L-asparaginase to patients who cannot tolerate current non-encapsulated
asparaginases.

Eryaspase in combination with chemotherapy achieved positive efficacy
and safety results in a Phase 2/3 study in children and adults with
relapsed or refractory ALL and in a Phase 2b clinical study in
second-line metastatic pancreatic cancer. ERYTECH also has an ongoing
Phase 1 clinical study of eryaspase in the United States in adults with
newly diagnosed ALL and a Phase 2b clinical study in Europe in elderly
patients with newly diagnosed acute myeloid leukemia (AML), each in
combination with chemotherapy.

ERYTECH produces eryaspase at its own GMP-approved and operational
manufacturing site in Lyon (France), and at a site for clinical
production in Philadelphia (USA). ERYTECH has entered into licensing and
distribution partnership agreements for eryaspase for ALL and AML in
Europe with Orphan Europe (Recordati Group), and for ALL in Israel with
TEVA, which will market the product under the GRASPA® brand name. The
European Medicines Agency (EMA) and the U.S. Food and Drug
Administration (FDA) have granted orphan drug designations for eryaspase
for the treatment of ALL, AML and pancreatic cancer.

In addition to eryaspase, ERYTECH is developing two other product
candidates, erymethionase and eryminase, that focus on using
encapsulated enzymes to target cancer metabolism and induce tumor
starvation. ERYTECH is also exploring the use of its ERYCAPS platform
for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement
therapies (ERYZYME).

ERYTECH is listed on the NASDAQ market in the United States under the
ticker ERYP. ERYTECH is also listed on Euronext regulated market in
Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the
CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable,
EnterNext PEA-PME 150 and Next Biotech indexes. .

Forward-looking information

This press release contains forward-looking statements, forecasts and
estimates with respect to the clinical development plans, business and
regulatory strategy, and anticipated future performance of ERYTECH and
of the market in which it operates. Certain of these statements,
forecasts and estimates can be recognized by the use of words such as,
without limitation, “believes”, “anticipates”, “expects”, “intends”,
“plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar
expressions. They include all matters that are not historical facts.
Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties
and other factors, which were deemed reasonable when made but may or may
not prove to be correct. Actual events are difficult to predict and may
depend upon factors that are beyond ERYTECH’s control. There can be no
guarantees with respect to pipeline product candidates that the
candidates will receive the necessary regulatory approvals or that they
will prove to be commercially successful. Therefore, actual results may
turn out to be materially different from the anticipated future results,
performance or achievements expressed or implied by such statements,
forecasts and estimates. Documents filed by ERYTECH Pharma with the
French Autorité des Marchés Financiers (www.amf-france.org),
also available on ERYTECH’s website (www.erytech.com)
describe such risks and uncertainties. Given these uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as of the
date of this press release. Readers are cautioned not to place undue
reliance on any of these forward-looking statements. ERYTECH disclaims
any obligation to update any such forward-looking statement, forecast or
estimates to reflect any change in ERYTECH’s expectations with regard
thereto, or any change in events, conditions or circumstances on which
any such statement, forecast or estimate is based, except to the extent
required by law.

Contacts

ERYTECH
Naomi Eichenbaum
Director of Investor
Relations
+33 4 78 74 44 38
+1 917 312 5151
naomi.eichenbaum@erytech.com
or
The
Ruth Group

Lee Roth
Investor relations
+1 646
536 7012
lroth@theruthgroup.com
or
Kirsten
Thomas

Media relations
+1 508 280 6592
kthomas@theruthgroup.com
or
NewCap
Julien
Perez

Investor relations
Nicolas Merigeau
Media
relations
+33 1 44 71 98 52
erytech@newcap.eu